Sugi Predict

Sugi Predict / Compounds / SCHEMBL2663593

SCHEMBL2663593

SCHEMBL2663593

Cc1cc(C)c(Cc2ccc(C(=O)NN(Cc3ccc(C(=O)NCCC(=O)O)cc3)c3ccc(C4CCCCC4)cc3)o2)c(C)c1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GCGR P47871 13/20 0.47
▸ OPRM1 P35372 1/20 0.39
▸ OPRK1 P41145 1/20 0.39
▸ GIPR P48546 7/20 0.38
▸ STAT3 P40763 2/20 0.36
▸ STAT1 P42224 1/20 0.36
▸ STAT5B P51692 1/20 0.36
▸ PPARG P37231 1/20 0.36
▸ PPARD Q03181 1/20 0.36
▸ PPARA Q07869 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ S1PR1 P21453 1/20 0.35
▸ S1PR3 Q99500 1/20 0.35
▸ S1PR5 Q9H228 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2663591 0.79 GCGR (0.51) GCGRGIPR
SCHEMBL4086780 0.79 GCGR (0.51) GCGRGIPR
SCHEMBL2663338 0.75 GCGR (0.59) GCGROPRM1OPRK1GIPRSTAT3
SCHEMBL2663083 0.74 GCGR (0.71) GCGRGIPRSTAT3
SCHEMBL2653321 0.72 GCGR (0.61) GCGROPRM1OPRK1GIPRSTAT3
SCHEMBL2663405 0.72 GCGR (0.62) GCGROPRM1OPRK1GIPRSTAT3
SCHEMBL9070861 0.72 GCGR (0.65) GCGROPRM1OPRK1GIPRSTAT3
SCHEMBL6755480 0.72 GCGR (0.65) GCGROPRM1OPRK1GIPRSTAT3
SCHEMBL9072895 0.71 GCGR (0.71) GCGRGIPR
SCHEMBL2666457 0.71 GCGR (0.60) GCGROPRM1OPRK1GIPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 — — EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 — — US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 — — US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 — — US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 — — US disclosed
WO-2000069810-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2000-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885OPRM1 826/4885OPRK1 493/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR GCGR 3/4885OPRM1 826/4885OPRK1 493/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885OPRM1 826/4885OPRK1 493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.